Clinical Trial

Aleniglipron Phase 2 Body Composition Study

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This is a randomized, double-blind, placebo-controlled study evaluating the effects of aleniglipron on body composition in participants living with obesity. Participants will be randomized to aleniglipron or placebo in a ratio of 5:1. Participants will receive multiple ascending QD doses of aleniglipron or placebo in titration steps of 4 weeks duration for a total of 40 weeks of treatment.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-09-11; most recent amendment 2026-02-27.
Status change: Recruiting → Active, Not Recruiting 2025-10-29
Trial Details
NCT Number NCT07169942
Lead Sponsor Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics
Conditions Obesity, Overweight, or Chronic Weight Management
Enrollment 71 participants
Start Date 2025-08-15
Primary Completion 2026-08 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2026-03-03